Celldex News, Celldex Quote, CLDX Quote

Celldex (NQ:CLDX) Delayed: 29.43 +0.07 (0.24%)

Prev. Close

$29.36

Today 6M 1Y 5Y

Open

$28.81

52 Wk High

$18.62

52 Wk Low

$2.85

Day High

$29.83

Day Low

$28.62

P/E

N/A

EPS

$-1.02

Volume

673,056

Friends, Peers and Foes (?): NBI ORKA (more...)

ALERTS | RSS

Mar 2, 2026 06:29 AM Celldex Therapeutics (CLDX) PT Raised to $34 at Goldman Sachs
Mar 1, 2026 09:45 AM Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) F
Feb 27, 2026 02:45 PM Celldex presents phase 2 data showing sustained efficacy for barzolvolimab
Feb 27, 2026 02:45 PM Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-
Feb 26, 2026 08:39 AM Celldex Therapeutics (CLDX) PT Raised to $44 at Morgan Stanley
Feb 25, 2026 04:08 PM Form 10-K Celldex Therapeutics, For: Dec 31
Feb 25, 2026 04:02 PM Form 8-K Celldex Therapeutics, For: Feb 25
Feb 25, 2026 04:01 PM Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Feb 25, 2026 07:35 AM Stifel Reiterates Buy Rating on Celldex Therapeutics (CLDX)
Feb 25, 2026 07:01 AM Celldex completes enrollment in phase 3 chronic urticaria studies

Entities mentioned with CLDX

View All Entities